Leap Therapeutics (LPTX) News Today → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free LPTX Stock Alerts $2.78 +0.03 (+1.09%) (As of 01:35 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 8:30 PM | markets.businessinsider.comBuy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic ExpansionMay 14 at 8:10 AM | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Given New $5.50 Price Target at HC WainwrightHC Wainwright decreased their price target on shares of Leap Therapeutics from $7.00 to $5.50 and set a "buy" rating for the company in a research note on Tuesday.May 13 at 2:33 PM | investorplace.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024May 13 at 8:20 AM | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13 at 7:00 AM | prnewswire.comLeap Therapeutics Reports First Quarter 2024 Financial ResultsMay 5, 2024 | americanbankingnews.comLeap Therapeutics (NASDAQ:LPTX) Trading Up 0.6%May 4, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Trading 0.6% Higher Leap Therapeutics (NASDAQ:LPTX) Trading Up 0.6%April 11, 2024 | markets.businessinsider.comLeap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%April 11, 2024 | prnewswire.comLeap Therapeutics Announces $40 Million Private PlacementMarch 26, 2024 | insidermonkey.com5 Best Biotech Penny Stocks to Invest InMarch 21, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Leap Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:LPTX)Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Leap Therapeutics in a report released on Tuesday, March 19th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.58)March 19, 2024 | markets.businessinsider.comLeap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy RatingMarch 19, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Leap Therapeutics in a report on Tuesday.March 19, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Price Target Cut to $9.00Robert W. Baird reduced their price target on shares of Leap Therapeutics from $11.00 to $9.00 and set an "outperform" rating on the stock in a research report on Tuesday.March 18, 2024 | investorplace.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023March 18, 2024 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | finance.yahoo.comLeap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comLPTX Apr 2024 5.000 callMarch 3, 2024 | marketbeat.comAcuta Capital Partners LLC Purchases New Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX)Acuta Capital Partners LLC purchased a new stake in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 354,166 shares of the company's stock, valued at approximaMarch 1, 2024 | marketbeat.com683 Capital Management LLC Has $676,000 Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)683 Capital Management LLC lifted its position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 60.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 490,000 shares of the compaFebruary 17, 2024 | finance.yahoo.comLPTX Mar 2024 7.000 callJanuary 31, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest UpdateLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 597,400 shares, a growth of 5.3% from the December 31st total of 567,300 shares. Based on an average daily volume of 257,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 2.5% of the company's stock are sold short.January 26, 2024 | markets.businessinsider.comOutperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial OutcomesJanuary 17, 2024 | msn.comEvolus, Leap Therapeutics among healthcare moversJanuary 16, 2024 | finance.yahoo.comLeap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumJanuary 6, 2024 | markets.businessinsider.comOptimism High as Leap Therapeutics’ Studies Suggest Potential for Significant Shareholder ValueJanuary 4, 2024 | ca.finance.yahoo.comLPTX Jun 2024 1.000 callJanuary 4, 2024 | ca.finance.yahoo.comLPTX Mar 2024 1.000 callJanuary 3, 2024 | finance.yahoo.comLeap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2024 | finance.yahoo.comLeap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsDecember 11, 2023 | finance.yahoo.comLeap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumNovember 21, 2023 | finance.yahoo.comLeap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comRaymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To KnowNovember 13, 2023 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | benzinga.comRecap: Leap Therapeutics Q3 EarningsNovember 13, 2023 | finance.yahoo.comLeap Therapeutics Reports Third Quarter 2023 Financial ResultsSeptember 5, 2023 | finance.yahoo.comLeap Therapeutics to Participate at Upcoming Investor ConferencesAugust 15, 2023 | msn.comHC Wainwright & Co. Maintains Leap Therapeutics (LPTX) Buy RecommendationAugust 15, 2023 | msn.comBaird Maintains Leap Therapeutics (LPTX) Outperform RecommendationAugust 15, 2023 | markets.businessinsider.comLeap Therapeutics (LPTX) Receives a Buy from H.C. WainwrightAugust 14, 2023 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 14, 2023 | finance.yahoo.comLeap Therapeutics Reports Second Quarter 2023 Financial ResultsJuly 14, 2023 | msn.comRaymond James Maintains Leap Therapeutics (LPTX) Outperform RecommendationJuly 12, 2023 | finance.yahoo.comLeap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer PatientsJuly 6, 2023 | msn.comLeap Therapeutics (LPTX) Price Target Increased by 876.00% to 24.89June 23, 2023 | markets.businessinsider.comLeap Therapeutics (LPTX) Receives a Buy from Raymond JamesJune 23, 2023 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Given New $17.00 Price Target at Raymond JamesRaymond James cut their target price on Leap Therapeutics from $20.00 to $17.00 in a research report on Friday.June 22, 2023 | marketwatch.com8-K: LEAP THERAPEUTICS, INC.June 21, 2023 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Announces Reverse Stock SplitJune 20, 2023 | finance.yahoo.comLeap Therapeutics Announces Reverse Stock Split Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address This is the best new way to score with AI (Ad)If you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open. Click now for the best way into the newest AI projects LPTX Media Mentions By Week LPTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPTX News Sentiment▼0.770.56▲Average Medical News Sentiment LPTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPTX Articles This Week▼91▲LPTX Articles Average Week Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Reviva Pharmaceuticals News Anebulo Pharmaceuticals News Affimed News Tempest Therapeutics News LifeVantage News SELLAS Life Sciences Group News Hookipa Pharma News vTv Therapeutics News Jaguar Health News Corvus Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPTX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport SocietyTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
